Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -299.21% is 57% above its 5-year average of -697.98%, near the high end of its 5-year range (-2873.09%–-22.84%).
67.38% below its 12-month average of -178.76%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -74.54%.
RETURN ON ASSETS (ROA)
-299.21%
RETURN ON ASSETS (ROA) AVG TTM
-178.76%
RETURN ON ASSETS (ROA) AVG 3Y
-127.09%
RETURN ON ASSETS (ROA) AVG 5Y
-697.98%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-67.38%
CURRENT VS 3Y AVG
-135.43%
CURRENT VS 5Y AVG
+57.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.73%
median of 688 covered companies
CURRENT VS SECTOR MEDIAN
-873.83%
vs the sector median at left
Nexalin Technology, Inc.
Market Cap
$3.55M
Return on Assets (ROA)
-299.21%
TTM Avg
-178.76%
3Y Avg
-127.09%
5Y Avg
-697.98%
Market Cap
$3.49M
Return on Assets (ROA)
-19.43%
TTM Avg
-90.07%
3Y Avg
-138.72%
5Y Avg
-110.42%
Market Cap
$3.45M
Return on Assets (ROA)
-8.01%
TTM Avg
-37.73%
3Y Avg
-92.58%
5Y Avg
-74.07%
Market Cap
$3.42M
Return on Assets (ROA)
-67.51%
TTM Avg
-41.84%
3Y Avg
-44.47%
5Y Avg
-41.13%
Market Cap
$3.34M
Return on Assets (ROA)
-206.55%
TTM Avg
-205.58%
3Y Avg
-343.02%
5Y Avg
-343.02%
Market Cap
$3.33M
Return on Assets (ROA)
-111.26%
TTM Avg
-147.41%
3Y Avg
-127.90%
5Y Avg
-106.52%
Market Cap
$3.28M
Return on Assets (ROA)
-95.33%
TTM Avg
-115.11%
3Y Avg
-93.94%
5Y Avg
-73.81%
Market Cap
$3.25M
Return on Assets (ROA)
-34.54%
TTM Avg
-27.85%
3Y Avg
-120.45%
5Y Avg
-88.60%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | $3.55M | -299.21% | -178.76% | -127.09% | -697.98% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -19.43% | -90.07% | -138.72% | -110.42% |
| Moolec Science S.A. (MLEC)vs › | $3.45M | -8.01% | -37.73% | -92.58% | -74.07% |
| Evogene Ltd. (EVGN)vs › | $3.42M | -67.51% | -41.84% | -44.47% | -41.13% |
| Eocene Ltd. (EOCN)vs › | $3.42M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.34M | -206.55% | -205.58% | -343.02% | -343.02% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.33M | -111.26% | -147.41% | -127.90% | -106.52% |
| IceCure Medical Ltd (ICCM)vs › | $3.28M | -95.33% | -115.11% | -93.94% | -73.81% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | -34.54% | -27.85% | -120.45% | -88.60% |
| MBody AI Ltd. (MBAI)vs › | $3.17M | 55.30% | -3307.76% | -1681.95% | -1351.74% |
ROA
-299.2%
ROE
-591.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -177.38% |
| 2024-12-31 | -180.15% |
| 2023-12-31 | -128.00% |
| 2022-12-31 | -22.84% |
| 2021-12-31 | -806.42% |
| 2020-12-31 | -2873.09% |
| 2019-12-31 | -4463.04% |
